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Executive Summary 
Osteoinductive therapeutic strategies are essential for the bone healing process 
and are applicable in multiple orthopaedic procedures. The novel protein Osteoactivin 
(OA) has proven to stimulate osteoblast differentiation and function in vitro and bone 
regeneration in vivo in the rat model. More recently, OA has shown significant bone 
regeneration ability in sheep. The goal of this study is the comparison of osteoactivin 
with bone morphogenetic protein-2 (BMP-2) in the rat spinal fusion model. Abdelmagid 
et al.  have shown that OA acts downstream of BMP-2. Additionally, a positive 1  
correlation was found between OA mRNA expression and protein production in 
response to treatment with BMP-2. Elimination of OA expression through the use of 
antisense OA oligonucleotides in the osteoblast cultures of  BMP-2 treated groups 
resulted in osteoblast differentiation similar to that of the control group. This 
demonstrates that BMP-2 has limited osteoinductive potential without the downstream 
protein, OA. If OA expression ceases, osteoblast differentiation and osteoinductive 
ability is reduced (to levels similar of the control group). These findings indicate that OA 
could function as an osteoblast-specific component of the BMP-2 cascade. This 
specificity is especially significant as targeting of OA in the BMP-2 cascade could 
prevent harmful side effects of general BMP-2 activation including nerve root injury, 
carcinogenesis, retrograde ejaculation and postoperative radiculitis. Autologous 2−6  
bone grafting was also utilized in this study to determine its effect on bone regeneration 
for OA and BMP-2. Autologous bone grafting is of limited value in pediatric and geriatric 
populations due to an increased risk of complications and limited amount of useable 
bone. Additional disadvantages with autologous bone grafting include the 7  
development of complications such as infection, hematoma, and fracture in 19% of 
patients that undergo iliac crest bone graft harvesting and 6% of patients that undergo 
reamer/irrigator/aspirator (RIA) harvest.   Comparison of the osteoinductive ability of 7  
OA and BMP-2  with and without autologous bone graft in rat spinal fusion occurred 
through the utilization of 70 male Sprague-Dawley rats. No study has previously 
compared OA and BMP2 in the spinal fusion model. 
Following the study, histological analysis revealed an absence of systemic 
inflammation and adverse health effects in Osteoactivin and Osteoactivin with 
autologous bone graft treatment groups. In contrast, increased inflammation was 
recognized in the bone morphogenetic protein-2 treatment groups.  
The aging population and the development of significant complications with bone 
morphogenetic protein-2 and autologous bone graft treatment compel more focused 
treatment options. BMP-2, an osteoinductive growth factor, has acquired an FDA listing 
of a warning of potential life-threatening complications.  Due to the risks of current 9  
treatment options, practitioners currently utilize compounds such as BMP-2 “off label.” 
This designation suggests that the practitioner is utilizing the compound in a manner 
that is inconsistent with the purpose specified on the label by the FDA. This use can be 
harmful to patient and practitioner alike. If OA can continue to be demonstrated as a 
viable osteoinductive compound, we will further investigate its therapeutic potential in 
other applicable osteogenesis surgeries and procedures. In the current situation of 
minimal clinically accepted osteoinductive treatments with the risk of significant adverse 
side effects, the performance of Osteoactivin in the stimulation of bone regeneration is 
important for the potential development of an improved therapeutic for osteoporotic 
patients and procedures requiring the use of osteogenesis. Clinical trials are the next 
step for Osteoactivin.  
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